More Severe Erosive Phenotype Despite Lower Circulating Autoantibody Levels in Dipeptidyl Peptidase-4 Inhibitor (DPP4i)-Associated Bullous Pemphigoid: A Retrospective Cohort Study-Reference-Cited by-同舟云学术

More Severe Erosive Phenotype Despite Lower Circulating Autoantibody Levels in Dipeptidyl Peptidase-4 Inhibitor (DPP4i)-Associated Bullous Pemphigoid: A Retrospective Cohort Study

Published:2020-10-07 Issue:1 Volume:22 Page:117-127
ISSN:1175-0561
Container-title:American Journal of Clinical Dermatology
language:en
Short-container-title:Am J Clin Dermatol

Author:

Ständer Sascha,Schmidt Enno,Zillikens Detlef,Ludwig Ralf J.,Kridin Khalaf^ORCID

Funder

Deutsche Forschungsgemeinschaft

Universität zu Lübeck

Publisher

Springer Science and Business Media LLC

Subject

Dermatology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s40257-020-00563-7.pdf

Reference29 articles.

1. Kridin K. Subepidermal autoimmune bullous diseases: overview, epidemiology, and associations. Immunol Res. 2018;66(1):6–17. https://doi.org/10.1007/s12026-017-8975-2.

2. Kridin K, Ludwig RJ. The growing incidence of bullous pemphigoid: overview and potential explanations. Front Med. 2018;5:220. https://doi.org/10.3389/fmed.2018.00220.

3. Benzaquen M, Borradori L, Berbis P, Cazzaniga S, Valero R, Richard M-A, et al. Dipeptidyl peptidase IV inhibitors, a risk factor for bullous pemphigoid: retrospective multicenter case-control study from France and Switzerland. J Am Acad Dermatol. 2018;78(6):1090–6. https://doi.org/10.1016/j.jaad.2017.12.038.

4. Varpuluoma O, Försti A-K, Jokelainen J, Turpeinen M, Timonen M, Huilaja L, et al. Vildagliptin significantly increases the risk of bullous pemphigoid: a Finnish nationwide registry study. J Invest Dermatol. 2018;138(7):1659–61. https://doi.org/10.1016/j.jid.2018.01.027.

5. Schaffer C, Buclin T, Jornayvaz FR, Cazzaniga S, Borradori L, Gilliet M, et al. Use of dipeptidyl-peptidase IV inhibitors and bullous pemphigoid. Dermatology. 2017;233(5):401–3. https://doi.org/10.1159/000480498.

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. DPP4‐Inhibitor‐assoziiertes bullöses Pemphigoid mit Ösophagusbeteiligung;JDDG: Journal der Deutschen Dermatologischen Gesellschaft;2024-03

2. Esophageal involvement in DPP4 inhibitor‐associated bullous pemphigoid;JDDG: Journal der Deutschen Dermatologischen Gesellschaft;2024-01-29

3. From Molecular Insights to Clinical Perspectives in Drug-Associated Bullous Pemphigoid;International Journal of Molecular Sciences;2023-11-26

4. Autoimmune pre-disease;Autoimmunity Reviews;2023-02

5. Dipeptidyl Peptidase 4 Inhibitor‒Associated Bullous Pemphigoid Is Characterized by an Altered Expression of Cytokines in the Skin;Journal of Investigative Dermatology;2023-01